Do analysts rate XBIT or TPST?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score XBiotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Tempest Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Which has better valuation and earnings, XBIT or TPST?

XBiotech is trading at a lower price-to-earnings ratio than Tempest Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio XBiotech N/A N/A -$45.54M -$1.48 N/A Tempest Therapeutics N/A N/A -$26.26M -$4.28 N/A

Is XBIT or TPST more profitable?

XBiotech's return on equity of -31.62% beat Tempest Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets XBiotech N/A -31.62% -30.29% Tempest Therapeutics N/A -576.56% -134.99%

Do analysts prefer PLRX or TPST?

Pliant Therapeutics presently has a consensus target price of $3.00, suggesting a potential upside of 165.49%. Given Pliant Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Pliant Therapeutics is more favorable than Tempest Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pliant Therapeutics 2 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.75 Tempest Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Is PLRX or TPST more profitable?

Pliant Therapeutics' return on equity of -52.17% beat Tempest Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Pliant Therapeutics N/A -52.17% -40.46% Tempest Therapeutics N/A -576.56% -134.99%

Do analysts rate IBIO or TPST?

iBio currently has a consensus price target of $5.00, suggesting a potential upside of 284.62%. Given iBio's stronger consensus rating and higher possible upside, equities research analysts clearly believe iBio is more favorable than Tempest Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score iBio 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 3 Strong Buy rating(s) 3.13 Tempest Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Is IBIO or TPST more profitable?

iBio's return on equity of -40.66% beat Tempest Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets iBio N/A -40.66% -35.78% Tempest Therapeutics N/A -576.56% -134.99%

Do analysts prefer TPST or EXOZ?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tempest Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 eXoZymes 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is TPST or EXOZ more profitable?

eXoZymes' return on equity of -292.15% beat Tempest Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Tempest Therapeutics N/A -576.56% -134.99% eXoZymes N/A -292.15% -158.66%

Do analysts rate TPST or RNTX?

Rein Therapeutics has a consensus target price of $6.00, indicating a potential upside of 611.24%. Given Rein Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Rein Therapeutics is more favorable than Tempest Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tempest Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Rein Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Which has higher earnings and valuation, TPST or RNTX?

Rein Therapeutics is trading at a lower price-to-earnings ratio than Tempest Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tempest Therapeutics N/A N/A -$26.26M -$4.28 N/A Rein Therapeutics N/A N/A -$49.87M -$1.72 N/A

Is TPST or RNTX more profitable?

Rein Therapeutics' return on equity of 0.00% beat Tempest Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Tempest Therapeutics N/A -576.56% -134.99% Rein Therapeutics N/A N/A -63.69%

Tempest Therapeutics (TPST) Competitors

$1.05 -0.05 (-4.55%)

As of 04:00 PM Eastern

Compare

TPST vs. XBIT, PLRX, IBIO, EXOZ, and RNTX

Should you buy Tempest Therapeutics stock or one of its competitors? Tempest Therapeutics's main competitors and comparable companies include XBiotech (XBIT), Pliant Therapeutics (PLRX), iBio (IBIO), eXoZymes (EXOZ), and Rein Therapeutics (RNTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Tempest Therapeutics compare to XBiotech?

XBiotech (NASDAQ:XBIT) and Tempest Therapeutics (NASDAQ:TPST) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, analyst recommendations, profitability, earnings, risk, institutional ownership, dividends and valuation.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
XBiotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Tempest Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

XBiotech has a beta of 0.85, suggesting that its share price is 15% less volatile than the broader market. Comparatively, Tempest Therapeutics has a beta of -1.68, suggesting that its share price is 268% less volatile than the broader market.

In the previous week, XBiotech had 2 more articles in the media than Tempest Therapeutics. MarketBeat recorded 2 mentions for XBiotech and 0 mentions for Tempest Therapeutics. XBiotech's average media sentiment score of 0.58 beat Tempest Therapeutics' score of 0.00 indicating that XBiotech is being referred to more favorably in the media.

Company	Overall Sentiment
XBiotech	Positive
Tempest Therapeutics	Neutral

XBiotech's return on equity of -31.62% beat Tempest Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
XBiotech	N/A	-31.62%	-30.29%
Tempest Therapeutics	N/A	-576.56%	-134.99%

55.7% of XBiotech shares are held by institutional investors. Comparatively, 22.5% of Tempest Therapeutics shares are held by institutional investors. 30.8% of XBiotech shares are held by insiders. Comparatively, 36.2% of Tempest Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

XBiotech is trading at a lower price-to-earnings ratio than Tempest Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
XBiotech	N/A	N/A	-$45.54M	-$1.48	N/A
Tempest Therapeutics	N/A	N/A	-$26.26M	-$4.28	N/A

Summary

XBiotech beats Tempest Therapeutics on 7 of the 11 factors compared between the two stocks.

How does Tempest Therapeutics compare to Pliant Therapeutics?

Pliant Therapeutics (NASDAQ:PLRX) and Tempest Therapeutics (NASDAQ:TPST) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, analyst recommendations, media sentiment, risk, earnings and profitability.

Pliant Therapeutics presently has a consensus target price of $3.00, suggesting a potential upside of 165.49%. Given Pliant Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Pliant Therapeutics is more favorable than Tempest Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pliant Therapeutics	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75
Tempest Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

97.3% of Pliant Therapeutics shares are owned by institutional investors. Comparatively, 22.5% of Tempest Therapeutics shares are owned by institutional investors. 8.7% of Pliant Therapeutics shares are owned by insiders. Comparatively, 36.2% of Tempest Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Pliant Therapeutics had 1 more articles in the media than Tempest Therapeutics. MarketBeat recorded 1 mentions for Pliant Therapeutics and 0 mentions for Tempest Therapeutics. Pliant Therapeutics' average media sentiment score of 0.59 beat Tempest Therapeutics' score of 0.00 indicating that Pliant Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Pliant Therapeutics	Positive
Tempest Therapeutics	Neutral

Pliant Therapeutics has a beta of 1.27, meaning that its stock price is 27% more volatile than the broader market. Comparatively, Tempest Therapeutics has a beta of -1.68, meaning that its stock price is 268% less volatile than the broader market.

Tempest Therapeutics has lower revenue, but higher earnings than Pliant Therapeutics. Pliant Therapeutics is trading at a lower price-to-earnings ratio than Tempest Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pliant Therapeutics	$1.58M	44.28	-$149.34M	-$1.49	N/A
Tempest Therapeutics	N/A	N/A	-$26.26M	-$4.28	N/A

Pliant Therapeutics' return on equity of -52.17% beat Tempest Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pliant Therapeutics	N/A	-52.17%	-40.46%
Tempest Therapeutics	N/A	-576.56%	-134.99%

Summary

Pliant Therapeutics beats Tempest Therapeutics on 11 of the 14 factors compared between the two stocks.

How does Tempest Therapeutics compare to iBio?

iBio (NASDAQ:IBIO) and Tempest Therapeutics (NASDAQ:TPST) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, media sentiment, earnings, profitability, analyst recommendations, valuation and risk.

7.9% of iBio shares are owned by institutional investors. Comparatively, 22.5% of Tempest Therapeutics shares are owned by institutional investors. 2.8% of iBio shares are owned by insiders. Comparatively, 36.2% of Tempest Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

iBio currently has a consensus price target of $5.00, suggesting a potential upside of 284.62%. Given iBio's stronger consensus rating and higher possible upside, equities research analysts clearly believe iBio is more favorable than Tempest Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iBio	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.13
Tempest Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

iBio has a beta of 1.29, suggesting that its stock price is 29% more volatile than the broader market. Comparatively, Tempest Therapeutics has a beta of -1.68, suggesting that its stock price is 268% less volatile than the broader market.

Tempest Therapeutics has lower revenue, but higher earnings than iBio. iBio is trading at a lower price-to-earnings ratio than Tempest Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iBio	$100K	645.84	-$33.04M	-$0.34	N/A
Tempest Therapeutics	N/A	N/A	-$26.26M	-$4.28	N/A

In the previous week, iBio had 15 more articles in the media than Tempest Therapeutics. MarketBeat recorded 15 mentions for iBio and 0 mentions for Tempest Therapeutics. iBio's average media sentiment score of 0.18 beat Tempest Therapeutics' score of 0.00 indicating that iBio is being referred to more favorably in the media.

Company	Overall Sentiment
iBio	Neutral
Tempest Therapeutics	Neutral

iBio's return on equity of -40.66% beat Tempest Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
iBio	N/A	-40.66%	-35.78%
Tempest Therapeutics	N/A	-576.56%	-134.99%

Summary

iBio beats Tempest Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Tempest Therapeutics compare to eXoZymes?

Tempest Therapeutics (NASDAQ:TPST) and eXoZymes (NASDAQ:EXOZ) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, valuation, institutional ownership, earnings, profitability and risk.

22.5% of Tempest Therapeutics shares are held by institutional investors. 36.2% of Tempest Therapeutics shares are held by insiders. Comparatively, 72.4% of eXoZymes shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

eXoZymes has higher revenue and earnings than Tempest Therapeutics. eXoZymes is trading at a lower price-to-earnings ratio than Tempest Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tempest Therapeutics	N/A	N/A	-$26.26M	-$4.28	N/A
eXoZymes	$70K	901.49	-$9.16M	-$1.19	N/A

In the previous week, eXoZymes had 2 more articles in the media than Tempest Therapeutics. MarketBeat recorded 2 mentions for eXoZymes and 0 mentions for Tempest Therapeutics. eXoZymes' average media sentiment score of 1.00 beat Tempest Therapeutics' score of 0.00 indicating that eXoZymes is being referred to more favorably in the news media.

Company	Overall Sentiment
Tempest Therapeutics	Neutral
eXoZymes	Positive

Tempest Therapeutics has a beta of -1.68, suggesting that its share price is 268% less volatile than the broader market. Comparatively, eXoZymes has a beta of 3.14, suggesting that its share price is 214% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tempest Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
eXoZymes	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

eXoZymes' return on equity of -292.15% beat Tempest Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tempest Therapeutics	N/A	-576.56%	-134.99%
eXoZymes	N/A	-292.15%	-158.66%

Summary

eXoZymes beats Tempest Therapeutics on 8 of the 12 factors compared between the two stocks.

How does Tempest Therapeutics compare to Rein Therapeutics?

Tempest Therapeutics (NASDAQ:TPST) and Rein Therapeutics (NASDAQ:RNTX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, media sentiment, dividends, analyst recommendations and earnings.

In the previous week, Rein Therapeutics had 2 more articles in the media than Tempest Therapeutics. MarketBeat recorded 2 mentions for Rein Therapeutics and 0 mentions for Tempest Therapeutics. Rein Therapeutics' average media sentiment score of 0.92 beat Tempest Therapeutics' score of 0.00 indicating that Rein Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Tempest Therapeutics	Neutral
Rein Therapeutics	Positive

Rein Therapeutics' return on equity of 0.00% beat Tempest Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tempest Therapeutics	N/A	-576.56%	-134.99%
Rein Therapeutics	N/A	N/A	-63.69%

Tempest Therapeutics has a beta of -1.68, indicating that its share price is 268% less volatile than the broader market. Comparatively, Rein Therapeutics has a beta of 1.37, indicating that its share price is 37% more volatile than the broader market.

Rein Therapeutics has a consensus target price of $6.00, indicating a potential upside of 611.24%. Given Rein Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Rein Therapeutics is more favorable than Tempest Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tempest Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Rein Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

22.5% of Tempest Therapeutics shares are held by institutional investors. Comparatively, 90.9% of Rein Therapeutics shares are held by institutional investors. 36.2% of Tempest Therapeutics shares are held by company insiders. Comparatively, 1.5% of Rein Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Rein Therapeutics is trading at a lower price-to-earnings ratio than Tempest Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tempest Therapeutics	N/A	N/A	-$26.26M	-$4.28	N/A
Rein Therapeutics	N/A	N/A	-$49.87M	-$1.72	N/A

Summary

Rein Therapeutics beats Tempest Therapeutics on 10 of the 13 factors compared between the two stocks.

Get Tempest Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TPST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TPST vs. The Competition

Export

Metric	Tempest Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$18.19M	$4.03B	$7.26B	$12.73B
Dividend Yield	N/A	3.60%	2.53%	8.86%
P/E Ratio	-0.25	12.66	273.28	25.38
Price / Sales	N/A	1,309.16	613.48	92.60
Price / Cash	N/A	106.87	77.82	52.26
Price / Book	-15.00	16.29	12.89	6.14
Net Income	-$26.26M	-$22.72M	$3.47B	$349.01M
7 Day Performance	-2.78%	-1.37%	-0.33%	-1.47%
1 Month Performance	19.99%	11.07%	6.51%	2.47%
1 Year Performance	-90.00%	53.71%	25.19%	15.84%

Tempest Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TPST Tempest Therapeutics	0.5756 of 5 stars	$1.05 -4.5%	N/A	-89.2%	$18.19M	N/A	N/A	20
XBIT XBiotech	0.4326 of 5 stars	$2.30 +1.3%	N/A	-27.5%	$69.21M	N/A	N/A	100	News Coverage Analyst Downgrade
PLRX Pliant Therapeutics	2.3052 of 5 stars	$1.10 -0.9%	$3.00 +172.7%	-30.7%	$68.73M	$1.58M	N/A	90
IBIO iBio	2.3588 of 5 stars	$1.27 -6.6%	$5.00 +293.7%	N/A	$67.56M	$100K	N/A	100	Earnings Report Upcoming Earnings Analyst Revision
EXOZ eXoZymes	1.4968 of 5 stars	$7.16 -0.1%	N/A	-29.9%	$66.53M	$70K	N/A	29	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TPST) was last updated on 9/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Tempest Therapeutics (TPST) Competitors

TPST vs. XBIT, PLRX, IBIO, EXOZ, and RNTX

How does Tempest Therapeutics compare to XBiotech?

Summary

How does Tempest Therapeutics compare to Pliant Therapeutics?

Summary

How does Tempest Therapeutics compare to iBio?

Summary

How does Tempest Therapeutics compare to eXoZymes?

Summary

How does Tempest Therapeutics compare to Rein Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TPST vs. The Competition

Tempest Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Tempest Therapeutics (TPST) Competitors

TPST vs. XBIT, PLRX, IBIO, EXOZ, and RNTX

How does Tempest Therapeutics compare to XBiotech?

Do analysts rate XBIT or TPST?

Which has more risk and volatility, XBIT or TPST?

Does the media prefer XBIT or TPST?

Is XBIT or TPST more profitable?

Do insiders & institutionals believe in XBIT or TPST?

Which has better valuation and earnings, XBIT or TPST?

Summary

How does Tempest Therapeutics compare to Pliant Therapeutics?

Do analysts prefer PLRX or TPST?

Do insiders & institutionals have more ownership in PLRX or TPST?

Does the media prefer PLRX or TPST?

Which has more volatility and risk, PLRX or TPST?

Which has preferable valuation & earnings, PLRX or TPST?

Is PLRX or TPST more profitable?

Summary

How does Tempest Therapeutics compare to iBio?

Do insiders and institutionals hold more shares of IBIO or TPST?

Do analysts rate IBIO or TPST?

Which has more risk and volatility, IBIO or TPST?

Which has better valuation & earnings, IBIO or TPST?

Does the media favor IBIO or TPST?

Is IBIO or TPST more profitable?

Summary

How does Tempest Therapeutics compare to eXoZymes?

Do insiders and institutionals hold more shares of TPST or EXOZ?

Which has higher valuation and earnings, TPST or EXOZ?

Does the media refer more to TPST or EXOZ?

Which has more risk & volatility, TPST or EXOZ?

Do analysts prefer TPST or EXOZ?

Is TPST or EXOZ more profitable?

Summary

How does Tempest Therapeutics compare to Rein Therapeutics?

Does the media favor TPST or RNTX?

Is TPST or RNTX more profitable?

Which has more volatility and risk, TPST or RNTX?

Do analysts rate TPST or RNTX?

Do institutionals and insiders believe in TPST or RNTX?

Which has higher earnings and valuation, TPST or RNTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TPST vs. The Competition

Tempest Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools